Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCORE DLBCL-2: epcoritamab + R-CHOP versus R-CHOP in newly diagnosed DLBCL
CTR20231627Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by AbbVie Inc.. Started Aug 2023; status: active.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20231627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231627.